Association of treatment with Carvedilol vs Metoprolol succinate and mortality in patients with heart failure

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1597-1604

  Pasternak, Bjorn ^a   Svanstrom, Henrik ^a   Melbye, Mads ^a,b   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; METOPROLOL SUCCINATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; METOPROLOL; PROPANOLAMINE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DEMOGRAPHY; DENMARK; DRUG EFFICACY; DRUG USE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROPENSITY SCORE; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CARBAZOLES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; ODDS RATIO; PROPANOLAMINES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84908008135     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3258     Document Type: Article

References (32)

1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169): 2001-2007.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
3. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22): 1651-1658.
4. McMurray JJ, Adamopoulos S, Anker SD, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology-developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-1847.
5. Yancy CW, Jessup M, Bozkurt B, et al;Writing Committee Members; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16): e240-e327.
6. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol. 2001;37(1):48-54.
7. Ohlstein EH, Arleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998;30(1):167-173.
8. Poole-Wilson PA, Swedberg K, Cleland JG, et al; Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
9. Dargie HJ. Beta blockers in heart failure. Lancet. 2003;362(9377):2-3.
10. Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet. 2003;362(9389): 1077-1078.
11. Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? a perspective on the results of the COMET trial. J Card Fail. 2003;9(6):429-443.
12. Wikstrand J, Fagerberg B, Goldstein S, Kjekshus J, Wedel H. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet. 2003;362(9389):1076-1077.
13. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.
14. Nakano A, Johnsen SP, Frederiksen BL, et al. Trends in quality of care among patients with incident heart failure in Denmark 2003-2010: a nationwide cohort study. BMC Health Serv Res. 2013;13:391.
15. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7)(suppl): 22-25.
16. Lynge E, Sandegaard JL, ReboljM. The Danish National Patient Register. Scand J Public Health. 2011;39(7)(suppl):30-33.
17. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7)(suppl):38-41.
18. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7) (suppl):26-29.
19. Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity scoremethods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604-611.
20. Harel O, Zhou XH. Multiple imputation: review of theory, implementation and software. Stat Med. 2007;26(16):3057-3077.
21. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
22. Fiuzat M, Wojdyla D, Kitzman D, et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012;60 (3):208-215.
23. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26 (21):2259-2268.
24. Wikstrand J, Hjalmarson A, Waagstein F, et al; MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol. 2002;40(3): 491-498.
25. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11): 784-794.
26. Tadrous M, Gagne JJ, Sturmer T, Cadarette SM. Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2013;22(2):122-129.
27. Parson LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Poster presented at: 26th Annual SAS Users Group International Conference; April 22-25, 2001; Long Beach, CA. http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
28. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(1):62-67.
29. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med. 2008;168(22):2415-2421.
30. Lazarus DL, Jackevicius CA, Behlouli H, Johansen H, Pilote L. Population-based analysis of class effect of β blockers in heart failure. Am J Cardiol. 2011;107(8):1196-1202.
31. Shore S, Aggarwal V, Zolty R. Carvedilol or sustained-releasemetoprolol for congestive heart failure: a comparative effectiveness analysis. J Card Fail. 2012;18(12):919-924.
32. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient datameta-analysis. Eur Heart J. 2012;33(14):1750-1757.